These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18294332)

  • 1. A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.
    Blasco H; Boisdron-Celle M; Bougnoux P; Calais G; Tournamille JF; Ciccolini J; Autret-Leca E; Le Guellec C
    Br J Clin Pharmacol; 2008 Jun; 65(6):966-70. PubMed ID: 18294332
    [No Abstract]   [Full Text] [Related]  

  • 2. Unanticipated toxicity to capecitabine.
    Moore S
    Oncol Nurs Forum; 2009 Mar; 36(2):149-52. PubMed ID: 19273404
    [No Abstract]   [Full Text] [Related]  

  • 3. [Severe capecitabine-associated toxicity in a patient carrying a mutation in the dihydropyrimidine dehydrogenase gen].
    González-Haba E
    Farm Hosp; 2012; 36(6):554-5. PubMed ID: 23461455
    [No Abstract]   [Full Text] [Related]  

  • 4. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.
    Magnani E; Farnetti E; Nicoli D; Casali B; Savoldi L; Focaccetti C; Boni C; Albini A; Banzi M
    Intern Emerg Med; 2013 Aug; 8(5):417-23. PubMed ID: 23585145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
    Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
    Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Suspected dihydropyrimidine dehydrogenase deficiency in a patient receiving capecitabine as adjuvant chemotherapy after colon resection].
    Nagai K; Okuda Y; Ohara Y; Yamamoto M
    Gan To Kagaku Ryoho; 2015 Jan; 42(1):127-9. PubMed ID: 25596695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule.
    Bank PC; Guchelaar HJ; Swen JJ
    Intern Emerg Med; 2014 Jun; 9(4):481-2. PubMed ID: 24310106
    [No Abstract]   [Full Text] [Related]  

  • 8. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
    Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
    Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
    Caudle KE; Thorn CF; Klein TE; Swen JJ; McLeod HL; Diasio RB; Schwab M
    Clin Pharmacol Ther; 2013 Dec; 94(6):640-5. PubMed ID: 23988873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
    Ostapowicz A; Dołegowska B
    Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of capecitabine-induced coronary microspasm in a patient with rectal cancer.
    Arbea L; Coma-Canella I; Martinez-Monge R; García-Foncillas J
    World J Gastroenterol; 2007 Apr; 13(14):2135-7. PubMed ID: 17465463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nursing considerations for capecitabine-based combination therapy.
    Becze E
    ONS Connect; 2009 Apr; 24(4):14-5. PubMed ID: 19413236
    [No Abstract]   [Full Text] [Related]  

  • 13. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency.
    Gbeto CC; Quaranta S; Mari R; Fanciullino R; Roche C; Nahon S; Solas C; Ouafik L; Lacarelle B; Allegre T; Ciccolini J
    Pharmacogenomics; 2019 Aug; 20(13):931-938. PubMed ID: 31486738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
    Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
    Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
    Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
    Loriot MA; Masskouri F; Carni P; Le Malicot K; Seitz JF; Michel P; Legoux JL; Bouché O; André T; Faroux R; Delaloge S; Malka D; Guigay J; Thariat J; Thomas F; Barin-Le-Guellec C; Ciccolini J; Boyer JC; Étienne-Grimaldi MC
    Bull Cancer; 2019 Sep; 106(9):759-775. PubMed ID: 31253356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
    Yang CG; Ciccolini J; Blesius A; Dahan L; Bagarry-Liegey D; Brunet C; Varoquaux A; Frances N; Marouani H; Giovanni A; Ferri-Dessens RM; Chefrour M; Favre R; Duffaud F; Seitz JF; Zanaret M; Lacarelle B; Mercier C
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):49-56. PubMed ID: 20204365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.
    Mokrim M; Aftimos PG; Errihani H; Piccart-Gebhart M
    BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24748142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of capecitabine-induced hyperpigmentation and radiation recall phenomenon.
    Ghosal N; Misra V
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):632. PubMed ID: 19304468
    [No Abstract]   [Full Text] [Related]  

  • 20. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
    Saif MW; Diasio R
    Clin Colorectal Cancer; 2006 Jan; 5(5):359-62. PubMed ID: 16512996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.